Table 1.
Analyte | RTa (min) | DPb (V) | Precursor ion (m/z) | For quantification | For conformation | ||||
---|---|---|---|---|---|---|---|---|---|
|
|
||||||||
Product ion (m/z) | CEc (eV) | CXPd (V) | Product ion (m/z) | CE (eV) | CXP (V) | ||||
Buqinolate | 15.8 | 50 | 361.8 | 204.0 | 50 | 20 | 260.2 | 40 | 20 |
Clopidol | 7.7 | 60 | 192.0 | 101.0 | 38 | 15 | 103.0 | 39 | 10 |
Closantel | 17.6 | −40 | 660.9 | 127.1 | −46 | −10 | 315.0 | −46 | −20 |
Decoquinate | 17.6 | 50 | 418.2 | 372.4 | 35 | 20 | 204.2 | 58 | 15 |
Diaveridine | 7.3 | 50 | 261.0 | 245.2 | 37 | 15 | 123.0 | 37 | 20 |
Dicalzuril | 15.1 | −40 | 407.0 | 335.9 | −26 | −20 | 334.1 | −26 | −20 |
Dimetridazole | 6.3 | 50 | 142.0 | 96.0 | 24 | 15 | 81.0 | 39 | 10 |
Diminazene aceturate | 7.4 | 30 | 282.2 | 119.2 | 26 | 15 | 135.2 | 13 | 15 |
Ethopabate | 11.5 | 30 | 238.0 | 135.9 | 39 | 15 | 206.0 | 16 | 15 |
Halofuginone | 11.4 | 50 | 416.1 | 100.1 | 30 | 15 | 120.2 | 30 | 15 |
Imidocarb | 6.9 | 60 | 349.2 | 145.0 | 76 | 20 | 188.2 | 46 | 15 |
Isometamidium | 10.4 | 60 | 460.3 | 313.2 | 29 | 20 | 298.3 | 31 | 20 |
Levamisole | 6.8 | 50 | 204.8 | 123.0 | 40 | 15 | 117.2 | 40 | 15 |
Metronidazole | 6.2 | 45 | 172.1 | 128.3 | 45 | 15 | 82.1 | 32 | 10 |
Nicarbazin | 14.4 | −60 | 301.0 | 137.2 | −20 | −15 | 107.1 | −50 | −15 |
Novobiocin | 16.1 | 65 | 613.1 | 189.3 | 65 | 20 | 396.3 | 22 | 20 |
Praziquantel | 14.3 | 50 | 313.1 | 203.3 | 50 | 10 | 174.2 | 40 | 15 |
Pyrantel pamoate | 7.9 | 50 | 207.1 | 150.1 | 50 | 15 | 136.1 | 42 | 15 |
Pyrimethamine | 10.6 | 40 | 249.0 | 177.1 | 40 | 10 | 198.2 | 55 | 25 |
Robenidine | 14.1 | 30 | 334.2 | 110.9 | 61 | 25 | 138.1 | 35 | 20 |
Zoalene | 9.0 | −40 | 224.1 | 181.1 | −15 | −20 | 151.3 | −22 | −20 |
RT: Retention time (min).
DP: Declustering potential.
CE: Collision energy.
CXP: Collision cell exit potential.